SMO and nevoid basal cell carcinoma syndrome: Our results indicate that this combination almost completely blocks the growth of these lesions, suggesting that combinatorial regimens utilizing Smo inhibitors and NSAIDS offer potentially superior benefit for patients with NBCCS.